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Treatment of hyperphosphatemia in patients with chronic kid-
ney disease on maintenance hemodialysis: Results of the CARE
study. Most patients with end-stage renal disease develop hyper-
phosphatemia because their dietary intake exceeds phosphorus
elimination by intermittent thrice-weekly dialysis. Inadequately
treated hyperphosphatemia plays a central role in the patho-
genesis of secondary hyperparathyroidism and extraosseous
calcification. Moreover, in the last 15 years, this biochemical
abnormality has become increasingly important following the
publication of two epidemiologic studies that demonstrated an
association between elevated serum phosphorus and increased
mortality risk in patients with end-stage renal disease. As a
result, the National Kidney Foundation Kidney Disease Out-
come and Quality Initiative (K/DOQI) Bone Metabolism and
Chronic Kidney Disease Guidelines recommend that serum
phosphorus levels be maintained between 3.5 and 5.5 mg/dL.
Unfortunately, cross-sectional studies have shown a mean
serum phosphorus of 6.2 mg/dL in the maintenance hemodial-
ysis population in the United States. An alarming 60% of pa-
tients have serum phosphorus in excess of the 5.5 mg/dL level
recommended by K/DOQI guidelines. In order to achieve this
new target for serum phosphorus, the most efficacious and
cost-effective phosphate binders currently available should be
utilized. In this review, we discuss the results of the Calcium
Acetate Renagel Evaluation (CARE study), which clearly
demonstrated the superiority of calcium acetate over sevelamer
hydrochloride for controlling serum phosphorus and calcium-
phosphate product to the levels recommended by the K/DOQI
guidelines.
Hyperphosphatemia has been clearly shown to play
a major role in the pathogenesis of secondary hyper-
parathyroidism, extraosseous calcification, and increased
mortality risk in hemodialysis patients. Serum phospho-
rus exceeding 5.5 mg/dL and calcium phosphate product
(Ca × P) over 52 mg2/dL2 each correlate with increased
mortality risk in dialysis patients [1]. These findings have
led to the recent publication of the National Kidney
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Foundation Kidney Disease Outcome and Quality Ini-
tiative (K/DOQI) Clinical Practice Guidelines for Bone
Metabolism and Disease in Chronic Kidney Disease,
which recommend more rigorous control of serum phos-
phorus to levels between 3.5 and 5.5 mg/dL, while main-
taining Ca × P product less than 55 mg2/dL2 [2].
Dietary restriction of phosphorus, although important,
is difficult to accomplish because dialysis patients are en-
couraged to consume a relatively high protein diet in
order to prevent protein malnutrition [3]. Similarly, inter-
mittent hemodialysis alone does not adequately control
serum phosphorus in most patients [4]. However, the use
of more frequent dialysis such as short daily dialysis or
long nocturnal hemodialysis may be effective in achieving
the recommended goal serum phosphorus level without
the use of phosphate binders [5]. Unfortunately, these
dialysis modalities are still in the experimental stage, and
have not yet been widely applied in clinical practice. Con-
sequently, phosphate binders are routinely prescribed for
most patients with end-stage renal disease (ESRD) in or-
der to reduce intestinal absorption of dietary phosphorus
and prevent hyperphosphatemia.
The ideal phosphate binder should bind most dietary
phosphate in the intestine without producing significant
adverse effects. It should also be relatively inexpen-
sive, because most dialysis patients usually consume rel-
atively large daily doses of the binder. Unfortunately,
none of the currently used phosphate binders fulfill all
these requirements. This is best exemplified by aluminum
hydroxide, which is probably the most cost-effective
phosphate binder but has largely been abandoned be-
cause of the risks of aluminum intoxication with en-
cephalopathy and osteomalacia. As a result, calcium
acetate and calcium carbonate replaced aluminum hy-
droxide as the most widely prescribed phosphate binders.
However, recent concern over the possible risks of cal-
cium loading from these binders has led to introduction
of the considerably more expensive non-calcium, non-
aluminum phosphate binder, sevelamer hydrochloride
(Renagel) [6].
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In clinical practice, calcium acetate and sevelamer hy-
drochloride are currently the two most commonly used
phosphate binders. Previous studies comparing these two
binders suggested that they are equally effective in con-
trolling serum phosphorus [6–10]. Unfortunately, previ-
ous trials did not allow for adequate comparison of these
binders because by design they were either open-label
[7, 9], single-arm titration [8], or placebo-controlled [4].
Moreover, in most of these studies, sevelamer hydrochlo-
ride was not usually effective in controlling serum phos-
phorus to the recommended goal of 5.5 mg/dL or less [7–
9]. Given the enormous financial burden of caring for the
ever-increasing dialysis population in the United States, it
is imperative that the newer and more expensive therapy
be shown to be at least equally efficacious in achieving the
desired goals for serum phosphorus before recommend-
ing it for widespread use in patients with chronic kidney
disease (CKD) on maintenance hemodialysis.
The CARE study
In order to compare the efficacy of calcium ac-
etate and sevelamer hydrochloride in controlling serum
phosphorus to the recently recommended goal level of
≤5.5 mg/dL, we conducted the Calcium Acetate Renagel
Evaluation (CARE) study. This is the only prospective,
randomized, double-blind study that directly compares
the efficacy of these two phosphate binders in patients on
maintenance hemodialysis [11].
Control of serum phosphorus
In the CARE study, calcium acetate was found to
be more effective than sevelamer hydrochloride for
control of serum phosphorus. In the calcium acetate–
treated patients, mean serum phosphorus decreased to
≤5.5 mg/dL after three weeks of titration, while in the
sevelamer-treated group, this goal was never achieved,
despite weekly dose escalation over the eight-week study
(Fig. 1). Moreover, beginning one week after the start
of treatment, and during each week, calcium acetate–
treated patients were 20% to 24% more likely to
achieve the goal serum phosphorus of ≤5.5 mg/dL than
sevelamer-treated group (weeks 1 to 8, summary OR 2.37,
95% CI 1.28–4.37, P value 0.0058). During the eight-
week treatment period, the median number of weeks with
the serum phosphorus goal attained was five weeks for
calcium acetate–treated group compared with one week
for the sevelamer hydrochloride group. The inadequate
serum phosphorus control in the sevelamer group could
not be explained by differences in compliance with binder
therapy as measured by pill counts. The starting doses of
these two binders were based on their respective package
insert recommendations for patients who are not receiv-
ing phosphate binders. Importantly, the prescribed daily
dose of sevelamer hydrochloride at week eight in our
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Fig. 1. Serum phosphorus control with calcium acetate or sevelamer
hydrochloride. Mean (±SE) serum phosphorus levels at baseline and
weekly during treatment with either calcium acetate () or sevelamer
hydrochloride (). At baseline, mean serum phosphorus levels were
not significantly different between the two groups (P = 0.99). Cal-
cium acetate reduced mean serum phosphorus below the target level of
5.5 mg/dL by the third week of treatment and maintained serum phos-
phorus below the target level until week eight. In the sevelamer hy-
drochloride treatment group, mean serum phosphorus never fell be-
low the target level throughout the eight-week treatment period. Over-
all, serum phosphorus levels were significantly lower during treatment
with calcium acetate than during treatment with sevelamer hydrochlo-
ride (1.08 mg/dL difference in Cavg during weeks 1–8, P value 0.0006
by covariate-adjusted regression). To convert values for phosphorus
to mmol per L, multiply by 0.32. Reprinted with permission from
Qunibi WY, Hootkins RE, McDowell LL, et al: Treatment of hyper-
phosphatemia in hemodialysis patients: The Calcium Acetate Renagel
Evaluation (CARE Study). Kidney Int 65:1914–1926, 2004.
study (6.9 ± 3.5 g per day) was comparable to that used
in the Treat to Goal study (6.5 ± 2.9 g per day) [10].
Our results are at variance from those of previous stud-
ies which suggested that these two binders were equally
efficacious in controlling serum phosphorus level [6, 7,
10]. However, these were open-label studies, and in at
least one, patients with serum phosphorus level exceeding
8.0 mg/dL were excluded [12]. Our results are in agree-
ment with two recent cross-sectional studies. Ciampi et al
reported the results of their long-term study of hemodial-
ysis patients in which they showed that the mean serum
phosphorus was significantly lower in calcium-containing
binder-treated patients compared with those treated with
sevelamer hydrocholoride [abstract; Ciampi MA et al,
J Am Soc Nephrol 13:586A, 2002]. Block et al reported
similar findings in their hemodialysis patients on long-
term phosphate binder therapy [abstract; Block GA
et al, J Am Soc Nephrol 12:761A, 2001].
Effect on serum calcium level
Although the efficacy of calcium acetate as a phosphate
binder has never been questioned, concern has recently
been expressed about its effect on raising serum calcium
levels and Ca × P product. Indeed, in the CARE study,
the serum calcium level was significantly higher in the
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Fig. 2. Serum calcium levels during treatment with calcium acetate or
sevelamer hydrochloride. Mean (±SE) serum calcium levels at base-
line and weekly during treatment with either calcium acetate () or
sevelamer hydrochloride (). At baseline, mean serum calcium was
not significantly different between the two groups (P = 0.84). Overall,
serum calcium levels were significantly higher during treatment with
calcium acetate than with sevelamer hydrochloride (0.63 mg/dL differ-
ence in Cavg during weeks 1–8, P value < 0.0001 by covariate-adjusted
regression). During treatment with either binder, mean serum calcium
levels remained within the normal range of 8.5 to 11 mg/dL. To convert
values for calcium to mmol per L, multiply by 0.25. Reprinted with per-
mission from Qunibi WY, Hootkins RE, McDowell LL, et al: Treatment
of hyperphosphatemia in hemodialysis patients: The Calcium Acetate
Renagel Evaluation (CARE Study). Kidney Int 65:1914–1926, 2004.
calcium acetate–treated patients compared to patients
treated with sevelamer hydrochloride (Fig. 2). Varying
among post baseline weeks one to eight, but with no ev-
ident time trend, at each week 2% to 9% of calcium
acetate–treated patients were hypercalcemic as defined
by serum calcium level ≥11.0 mg/dL. By contrast, no pa-
tient in the sevelamer-treated group developed hypercal-
cemia. Regression analysis confirmed that hypercalcemia
was more likely to develop in the calcium acetate group
(summary OR 6.1, 95% CI 2.8–13.3, P value < 0.0001).
Overall, transient hypercalcemia developed in eight of
48 (16.7%) calcium acetate–treated patients. It should
be noted that hypercalcemia occurred only in calcium
acetate–treated patients concomitantly treated with in-
travenous vitamin D preparations. Hypercalcemia was
not observed in patients not on vitamin D therapy.
In contrast, hypocalcemia developed more frequently
in sevelamer-treated patients. Varying among post-
baseline weeks one to eight, but with no evident time
trend, at each treatment week 7% to 24% of sevelamer
hydrochloride-treated patients experienced hypocal-
cemia, defined as serum calcium level ≤8.5 mg/dL,
compared with 2% to 13% of calcium acetate–treated pa-
tients. Overall, 50% of sevelamer-treated patients had at
least one episode of hypocalcemia compared with 27% of
the calcium acetate–treated patients. The pathogenesis of
hypocalcemia in sevelamer-treated patients has not been
carefully studied. However, it is possible that in the seve-
lamer hydrochloride group withdrawal of calcium-based
binders in the washout period was sufficient to cause a net
negative calcium balance and hypocalcemia in patients on
maintenance hemodialysis with dialysate calcium fixed at
2.5 mEq/L.
The long-term sequelae of chronic hypocalcemia in
sevelamer-treated patients are currently being debated.
Lowrie and Lew reported that serum calcium level
<8.8 mg/dL was associated with a nearly three-fold in-
crease in the mortality risk [13]. Similarly, Foley et al
found an association between low serum calcium level
and the risk of death [14]. To avoid hypocalcemia, Cher-
tow et al have recommended that patients treated with
sevelamer receive a nighttime supplement of 900 mg of el-
emental calcium per day [15]. In this regard, when 900 mg
elemental calcium is administered at night on an empty
stomach as much as 40% (360 mg) may be absorbed [16].
In contrast, when calcium acetate is administered with
meals as a phosphate binder, only 15% to 20% of the
elemental calcium is absorbed [17], such that with the av-
erage daily dose required in the CARE study (7 g calcium
acetate containing 1750 mg elemental calcium), approxi-
mately 350 mg calcium would be absorbed. Thus, patients
taking sevelamer along with supplemental nocturnal cal-
cium carbonate would be likely to absorb as much cal-
cium as patients receiving calcium acetate with meals as
a phosphate binder. It would be more logical to admin-
ister required calcium supplements with meals as part of
an overall phosphate-binding regimen [18].
Control of calcium-phosphorus product (Ca × P)
Because treatment with calcium acetate leads to a slight
increase in serum calcium levels, concern has been raised
that this will result in higher Ca × P product, which may
predispose to extraosseous calcification. Of more concern
is the report by Block et al, who showed that hemodialy-
sis patients in the highest Ca × P quintiles (73 to 132 mg2/
dL2) had a 34% increased risk of death compared with
patients in the 43 to 52 mg2/dL2 reference range [1]. For
each 10 mg2/dL2 increase in Ca × P product, there was
a 6% increase in the mortality risk and 7% increase in
the risk of sudden death [19]. However, in the CARE
study we found that despite higher mean serum calcium
levels, calcium acetate–treated patients consistently had
lower mean Ca × P products, and more often achieved the
K/DOQI treatment goal (≤55 mg2/dL2) than sevelamer-
treated patients (Fig. 3). Even among the subgroup of
patients with baseline Ca × P product greater than
70 mg2/dL2, treatment with calcium acetate resulted in
more rapid reduction in Ca × P product than treatment
with sevelamer hydrochloride. Each week, calcium ac-
etate recipients were 15% to 20% more likely to attain the
Ca × P goal than sevelamer-treated patients (weeks 1 to
8, summary OR 2.16, 95% CI 1.20–3.86, P value 0.0097).
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Fig. 3. Calcium × phosphorus products during treatment with calcium
acetate or sevelamer hydrochloride. Mean serum calcium × phospho-
rus product at baseline and weekly during treatment with either cal-
cium acetate () or sevelamer hydrochloride (). At baseline, Ca ×
P product was not significantly different between the two groups (P =
0.91). However, Ca×P product was significantly lower during treatment
with calcium acetate than with sevelamer hydrochloride (6.1 mg2/dL2
difference in Cavg during weeks 1–8, P value < 0.0001 by covariate-
adjusted regression). To convert from units of mg2/dL2 to mmol2/L2,
multiply by 0.08. Repinted with permission from Qunibi WY, Hootkins
RE, McDowell LL, et al: Treatment of hyperphosphatemia in hemodial-
ysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).
Kidney Int 65:1914–1926, 2004.
The median number of weeks of goal attained for Ca ×
P product was four weeks in the calcium acetate group
compared with one week for the sevelamer hydrochlo-
ride group. Our results are in accord with the findings in
the Treat-to-Goal study, in which the mean Ca × P prod-
uct in patients treated with calcium-containing phosphate
binders was 49 ± 14 mg2/dL2 [10].
Effects on parathyroid hormone (iPTH) levels
Secondary hyperparathyroidism is common in patients
with chronic kidney disease on maintenance hemodial-
ysis. Given that serum ionized calcium is the primary
regulator of PTH secretion, and that treatment with cal-
cium acetate is associated with a slight increase in serum
calcium levels, it has been suggested that its use may
oversuppress serum iPTH levels, thus predisposing to the
development of adynamic bone disease [10, 20, 21]. How-
ever, our findings in the CARE study do not substanti-
ate this claim. At baseline, the geometric mean (GM)
iPTH level was 263 ± 161 pg/mL in the calcium acetate
group compared with 199 ± 125 pg/mL in the sevelamer
group (P = 0.15). Both phosphate binders significantly
decreased iPTH levels compared to baseline. In the cal-
cium acetate group, GM iPTH declined 37% from base-
line to week four but only 6% more in weeks four to
eight. In the sevelamer group, GM iPTH declined 6%
from baseline to week four and 11% in weeks four to
eight. There was no significant difference in GM iPTH
levels between the two groups at the end of the study.
At week eight, GM iPTH was 177 ± 137 pg/mL in the
calcium acetate groups compared with 164 ± 110 pg/mL
in the sevelamer group (P = 0.12). Thus, we found no
evidence of oversuppression of iPTH in calcium acetate–
treated patients.
Combined efficacy end points
Calcium acetate was significantly more effective than
sevelamer in achieving combined efficacy end points
which included phosphorus control, Ca × P product, and
maintenance of serum calcium in the usual normal range
(8.5 to 11 mg/dL) (Fig. 4). Neither binder was very effec-
tive in achieving any combined efficacy end points which
included the recently proposed narrower range for serum
calcium (9.2 to 9.6 mg/dL) [20] or the recommended iPTH
treatment goal (100 to 200 pg/mL) (Fig. 4).
Limitations of the CARE study
One of the main limitations of this study is the relatively
short eight-week treatment period. However, the doses
of calcium acetate and sevelamer used in the CARE study
were similar to those employed in longer term phosphate
binder studies [10]. Moreover, a recent cross-sectional
study of hemodialysis patients treated with sevelamer hy-
drochloride for longer than one year (mean 23 months,
range 13 to 40 months) revealed that in comparison to pa-
tients treated with calcium-containing phosphate binders,
sevelamer-treated patients had higher serum phosphorus
levels (6.5 ± 1.2 vs. 5.4 ± 1.5 mg/dL; P < 0.05), higher Ca
× P products (62.1 ± 16 vs. 49.7 ± 14.6 mg2/dL2; P <
0.05), and lower serum bicarbonate levels (18.6 ± 2.7 vs.
20.3 ± 1.8 mEq/L; P < 0.05) [abstract; Ciampi MA et al,
J Am Soc Nephrol 13:586A, 2002]. Very similar findings
were reported in another cross-sectional study compar-
ing hemodialysis patients treated with either sevelamer
or calcium-containing binders [abstract; Block GA, J Am
Soc Nephrol 12:761A, 2001]. Given the short-term na-
ture of the CARE study, meaningful examination of the
effects of calcium acetate and sevelamer on progression
of cardiovascular calcification is not possible. This im-
portant issue can only be addressed by well-designed,
double-blind studies which control for not only the type
of phosphate binder, but also for the myriad risk factors
potentially associated with cardiovascular calcification,
including dialysate calcium level, vitamin D usage, and
treatment of hyperlipidemia [22]. This subject is discussed
in greater details in two other papers in this supplement
(Qunibi, McCullough).
Cost considerations
The cost of phosphate binder therapy remains an im-
portant issue. Based on week eight doses and average
wholesale prices for PhosLo (667 mg capsules; Nabi
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Fig. 4. Efficacy end points during treatment with calcium acetate or sevelamer hydrochloride. In order to determine the efficacy of calcium acetate
(open bars) or sevelamer hydrochloride (closed bars) in achieving and maintaining the recently recommended treatment goals of serum phosphorus
between 2.5 to 5.5 mg/dL, calcium-phosphorus product (Ca × P) ≤55 mg2/dL2, serum calcium 9.2 to 9.6 mg/dL, and iPTH 100 to 200 pg/mL, we
defined selected efficacy end points that consisted of either individual or various combinations of these treatment goals. We also analyzed our
data with end points that included serum calcium levels in the generally accepted normal range of 8.5 to 11 mg/dL. For each of these efficacy end
points, we calculated the mean number of treatment weeks that individual subjects in the two treatment groups in the CARE study successfully
achieved the treatment goals. Statistical analysis by analysis of variance (ANOVA) revealed that calcium acetate was significantly more effective
than sevelamer hydrochloride in achieving the individual treatment goals for serum phosphorus, and Ca × P product. Moreover, calcium acetate
was also significantly more effective than sevelamer hydrochloride in achieving the combined efficacy end points for phosphorus and Ca × P; and
the triple end point of phosphorus, Ca × P product, and usual normal range calcium. Neither binder was effective in achieving any combined efficacy
end point that included the narrow calcium range (9.2 to 9.6 mg/dL) or the recommended iPTH goal. (Asterisks indicate a significant difference
between the two treatment groups as defined by P < 0.05)
Biopharmaceuticals, Boca Raton, FL, USA) and
Renagel (403 mg capsules; Genzyme Corporation,
Cambridge, MA, USA) [23], the projected annual per
patient cost for treatment with calcium acetate would
be $732 compared with $4283 for sevelamer. Thus, if
sevelamer were to be adopted as the first-line phosphate
binder, the cost for treatment of the roughly 270,000 dial-
ysis patients in the United States would increase by over
1.0 billion dollars per year. Although the lipid-lowering
effect of sevelamer may have a beneficial role in slowing
the progression of cardiovascular calcification in dialy-
sis patients [10], cost-benefit analysis reveals that com-
bined treatment with an HMG-CoA reductase inhibitor
and calcium-containing phosphate binder would be a far
more cost-effective alternative.
CONCLUSION
Results of the CARE study, the only prospective, ran-
domized, double-blind study comparing the only two
FDA-approved phosphate binders, has definitively es-
tablished the superiority of calcium acetate over seve-
lamer hydrochloride for achieving the target levels of
serum phosphorus and Ca × P product recommended by
K/DOQI guidelines. Moreover, calcium acetate appears
to be the more cost-effective choice as first-line treatment
for hyperphosphatemia in patients with ESRD on main-
tenance dialysis. The doses of calcium acetate required for
control of serum phosphorus fall within the 1500 to 2000
mg of elemental calcium intake per day recommended by
the K/DOQI guidelines. Nevertheless, in the occasional
patient who develops persistent hypercalcemia during
treatment with calcium acetate despite appropriate re-
duction in vitamin D dosage and adjustment of dialysate
calcium level, it may be prudent to reduce the dose of cal-
cium acetate and add a non-calcium–containing binder
such as sevelamer hydrochloride [18].
Reprint requests to Wajeh Y. Qunibi, M.D., Professor of Medicine, De-
partment of Medicine/Nephrology Division, University of Texas Health
Sciences Center at San Antonio, 7703 Floyd Curl Drive, San Antonio,
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